3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Dexamethasone
48
Calcium Dobesilate
20
Bortezomib
20
Lenalidomide
19
Melphalan
16
daratumumab
11
Cyclophosphamide
11
pomalidomide
10
elotuzumab
8
carfilzomib
8
dexamethasone acetate
7
pembrolizumab
6
ixazomib
6
fludarabine phosphate
6
dexamethasone 21-phosphate
6
venetoclax
5
selinexor
5
fludarabine
5
auricularum
5
Filgrastim
5
liposomal doxorubicin
4
Thalidomide
4
Tacrolimus
4
Peripheral Blood Stem Cell Transplantation
4
Magnetic Resonance Spectroscopy
4
Whole-Body Irradiation
3
Vorinostat
3
Simvastatin
3
Nivolumab
3
Mycophenolic Acid
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
crexavibart
×
Plasma cell
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn